Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

- Reports Further Details from Phase 1a SAD Clinical Study -

BRISBANE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced that the company has begun dosing the first patients in their Phase 1b multiple ascending dose (MAD) clinical trial evaluating ITMN-191 (also called R7227) in patients with chronic hepatitis C. ITMN-191 is a hepatitis C virus (HCV) protease inhibitor in development by InterMune and its partner, Roche. InterMune also reported additional information from its recently completed Phase 1a clinical trial of ITMN-191.

Dan Welch, President and Chief Executive Officer of InterMune, said, "We are pleased to have successfully initiated the very important Phase 1b multiple ascending dose study of ITMN-191." Mr. Welch continued, "This is our first opportunity to evaluate the effects of ITMN-191 on viral kinetics in HCV patients, and to gather additional safety information beyond the recently completed Phase 1a SAD study. We look forward to sharing top-line results from the three treatment-nave dose cohorts of the Phase 1b study in the first quarter of 2008."

Phase 1b Trial Design

The Phase 1b placebo-controlled study is anticipated to enroll approximately 40 HCV patients. The study will assess the effect of multiple doses of ITMN-191 given as a monotherapy on viral kinetics, viral resistance, pharmacokinetics, safety and tolerability. Patients will be administered ITMN-191 twice per day (BID) or three-times per day (TID) with a meal for a period of 14 days. Three ascending dose cohorts of treatment-naive chronic hepatitis C patients infected with HCV genotype 1 will be enrolled. In addition, a single cohort of treatment-experienced chronic hepatitis
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Terumo Heart, Inc. announced,today that they have ... Drug,Administration (FDA) to begin enrollment in the ... for a Bridge-to-Transplant (BTT) indication., (Logo: ... http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 ), Dr. David Munjal, ...
... 29 Eisai Corporation of,North America, a wholly-owned ... the Food and Drug Administration (FDA) has accepted ... short-term (up to,eight weeks) treatment of gastroesophageal reflux ... indicated that the sNDA will receive,priority review in ...
Cached Medicine Technology:DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial 2FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents 2
(Date:7/12/2014)... July 12, 2014 Dubai is buzzing ... legend is heading to the UAE. The National ... will be in the UAE from 28-31 October to ... support of diabetes awareness. The event is being organized ... and event management company based in Dubai. The announcement ...
(Date:7/12/2014)... Praeclarus Press is excited to offer ... resource for women in need of lactation support. Statistics ... from their children. Today’s mothers receive very clear messages ... often feel unsupported when it comes to balancing working ... insights, and written by Nancy Mohrbacher, an international breastfeeding ...
(Date:7/12/2014)... 12, 2014 Restore My Vision Today ... Samantha Pearson, a couple boasting very impressive credentials on ... My Vision Today as a way to help consumers ... become in their respective patients’ treatments . ... a “secret” trove of pertinent information relevant to eye ...
(Date:7/12/2014)... Palm Beach, FL (PRWEB) July 12, 2014 ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, the trendy ... an affordable gown can visit Discount-Dress.com (a reliable ... dream items. Recently, the company has announced its new selection ... that, it is also providing great discounts for these unique ... of this promotion is July 29, 2014. , Discount-Dress.com ...
Breaking Medicine News(10 mins):Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... (PHILADELPHIA) An immune system messenger molecule that normally helps ... multiple sclerosis (MS). Neurology researchers led by Abdolmohamad ... Department of Neurology at Jefferson Medical College of ... Neuroscience in Philadelphia, have found that the protein ...
... New research provides clues about the causes of lupus ... to Nilamadham Mishra, M.D., from Wake Forest University Baptist ... College of Rheumatology in Boston. , The studies looked ... accelerated cell death that seems to be behind many ...
... at NOCC Annual Conference in Houston, TX November ... the National Ovarian Cancer,Coalition, Inc. (NOCC) Board of ... regional offices to better support its network of,80 ... administrative and management,responsibilities will be transitioning to an ...
... leading EMR now offers rapid start-ups, without forcing doctors into ... ... Calif., Nov. 9 Infor-Med Corporation,today announced the pre-release of Praxis ... The dynamic,tool allows physicians to tap into the knowledge of other ...
... YORK, Nov. 9 Many Americans are currently ... health benefits. But they still feel,aches and pains ... can affect which pain,relievers they can use. ... Registered journalists can access video, audio, ...
... Council on,Disability (NCD) today invited the Boston disability community ... take place at,the Hyatt Regency Boston, One Avenue de ... a.m. until 5:00 p.m.; Friday,November 30 from 8:30 a.m. ... until 11:15 a.m., Public comment sessions will be ...
Cached Medicine News:Health News:Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease 2Health News:Research suggests targeted treatment strategies for lupus 2Health News:Infor-Med, Inc. Announces New Praxis EMR Version 4 with The Praxis Knowledge Exchanger(R) 2
Inquire...
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: